Clade-specific variation in susceptibility of


Journal

Infection control and hospital epidemiology
ISSN: 1559-6834
Titre abrégé: Infect Control Hosp Epidemiol
Pays: United States
ID NLM: 8804099

Informations de publication

Date de publication:
12 2020
Historique:
pubmed: 14 10 2020
medline: 1 9 2021
entrez: 13 10 2020
Statut: ppublish

Résumé

Candida auris is an emerging and often multidrug-resistant fungal pathogen with an exceptional ability to persist on hospital surfaces. These surfaces can act as a potential source of transmission. Therefore, effective disinfection strategies are urgently needed. We investigated the efficacy of ultraviolet C light (UV-C) disinfection for C. auris isolates belonging to 4 different clades. In vitro testing of C. auris isolates was conducted using 106 colony-forming units (CFU) spread on 20-mm diameter steel carriers and exposed to a broad-spectrum UV-C light source for 10, 20, and 30 minutes at a 1.5 m (5 feet) distance. Post-UV survivors on the coupons were subsequently plated. Colony counts and log reductions were recorded, calculated, and compared to untreated control carriers. Identification of all isolates were confirmed by MALDI-TOF and morphology was visualized by microscopy. We observed an increased susceptibility of C. auris to UV-C in 8 isolates belonging to clades I, II and IV with increasing UV exposure time. The range of log kill (0.8-1.19) was highest for these isolates at 30 minutes. But relatively no change in log kill (0.04-0.35) with increasing time in isolates belonging to clade III were noted. Interestingly, C. auris isolates susceptible to UV-C were mostly nonaggregating, but the isolates that were more resistant to UV exposure formed aggregates. Our study suggests variability in susceptibility to UV-C of C. auris isolates belonging to different clades. More studies are needed to assess whether a cumulative impact of prolonged UV-C exposure provides additional benefit.

Sections du résumé

BACKGROUND
Candida auris is an emerging and often multidrug-resistant fungal pathogen with an exceptional ability to persist on hospital surfaces. These surfaces can act as a potential source of transmission. Therefore, effective disinfection strategies are urgently needed. We investigated the efficacy of ultraviolet C light (UV-C) disinfection for C. auris isolates belonging to 4 different clades.
METHODS
In vitro testing of C. auris isolates was conducted using 106 colony-forming units (CFU) spread on 20-mm diameter steel carriers and exposed to a broad-spectrum UV-C light source for 10, 20, and 30 minutes at a 1.5 m (5 feet) distance. Post-UV survivors on the coupons were subsequently plated. Colony counts and log reductions were recorded, calculated, and compared to untreated control carriers. Identification of all isolates were confirmed by MALDI-TOF and morphology was visualized by microscopy.
RESULTS
We observed an increased susceptibility of C. auris to UV-C in 8 isolates belonging to clades I, II and IV with increasing UV exposure time. The range of log kill (0.8-1.19) was highest for these isolates at 30 minutes. But relatively no change in log kill (0.04-0.35) with increasing time in isolates belonging to clade III were noted. Interestingly, C. auris isolates susceptible to UV-C were mostly nonaggregating, but the isolates that were more resistant to UV exposure formed aggregates.
CONCLUSIONS
Our study suggests variability in susceptibility to UV-C of C. auris isolates belonging to different clades. More studies are needed to assess whether a cumulative impact of prolonged UV-C exposure provides additional benefit.

Identifiants

pubmed: 33046172
pii: S0899823X20004109
doi: 10.1017/ice.2020.410
pmc: PMC7720409
doi:

Substances chimiques

Antifungal Agents 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1384-1387

Références

J Mycol Med. 2018 Sep;28(3):568-573
pubmed: 30030072
Microbiol Immunol. 2009 Jan;53(1):41-4
pubmed: 19161556
J Hosp Infect. 2018 Apr;98(4):433-436
pubmed: 29203448
Pathog Immun. 2019 Oct 28;4(2):260-270
pubmed: 31768483
Infect Control Hosp Epidemiol. 2017 Oct;38(10):1240-1243
pubmed: 28793937
Clin Infect Dis. 2017 Nov 13;65(11):1954-1955
pubmed: 29020154
Mycoses. 2019 May;62(5):408-412
pubmed: 30748018
Curr Opin Microbiol. 2019 Dec;52:84-89
pubmed: 31279224
J Clin Microbiol. 2019 Apr 26;57(5):
pubmed: 30867237
mSphere. 2016 Aug 18;1(4):
pubmed: 27547827
Infect Control Hosp Epidemiol. 2017 Sep;38(9):1107-1109
pubmed: 28693657
Curr Opin Infect Dis. 2019 Dec;32(6):559-564
pubmed: 31592823
Infect Control Hosp Epidemiol. 2018 Jan;39(1):94-96
pubmed: 29157326
Infect Control Hosp Epidemiol. 2015 Feb;36(2):192-7
pubmed: 25633002
BMC Infect Dis. 2019 Jun 19;19(1):540
pubmed: 31216988
MMWR Morb Mortal Wkly Rep. 2017 May 19;66(19):514-515
pubmed: 28520710

Auteurs

Piyali Chatterjee (P)

Department of Research, Central Texas Veterans' Health Care System, Temple, Texas.

Hosoon Choi (H)

Department of Research, Central Texas Veterans' Health Care System, Temple, Texas.

Brennan Ochoa (B)

Department of Research, Central Texas Veterans' Health Care System, Temple, Texas.
Infectious Diseases, Baylor Scott and White Memorial Healthcare, Temple, Texas.

Gennifer Garmon (G)

Department of Research, Central Texas Veterans' Health Care System, Temple, Texas.
Infectious Diseases, Baylor Scott and White Memorial Healthcare, Temple, Texas.

John D Coppin (JD)

Department of Research, Central Texas Veterans' Health Care System, Temple, Texas.

Yonhui Allton (Y)

Department of Research, Central Texas Veterans' Health Care System, Temple, Texas.

Janell Lukey (J)

Department of Medicine, Central Texas Veterans' Health Care System, Temple, Texas.

Marjory D Williams (MD)

Department of Research, Central Texas Veterans' Health Care System, Temple, Texas.

Dhammika Navarathna (D)

Department of Medicine, Central Texas Veterans' Health Care System, Temple, Texas.

Chetan Jinadatha (C)

Department of Research, Central Texas Veterans' Health Care System, Temple, Texas.
Department of Medicine, Central Texas Veterans' Health Care System, Temple, Texas.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH